|
Pennsaid Plus (NRI-1004)
Nuvo began exploring formulations to improve upon the original Pennsaid® formulation in late 2004.
The Corporation has conducted preliminary testing of several potential improved versions of Pennsaid®, currently
referred to as NRI-1004 or Pennsaid Plus. While no clinical trials of this product have taken place to date, in vitro
testing has indicated that NRI-1004 can significantly increase the transport of diclofenac, the active
therapeutic drug in both Pennsaid® and NRI-1004, through the skin. The development of NRI-1004
is an important step in the Corporation’s plan to develop a family of topically applied transdermally delivered
drugs with applications across serveral of therapeutic areas.
NRI-1004 is designed to provide users with the efficacy of existing
Pennsaid® , with less frequent dosing and increased ease of application.
Patent applications for NRI-1004 have been filed and a pivotal phase III trial for the product is planned.
|